JAMA Neurology publishes Synchron's four-patient Australian study: no serious adverse events causing death or lasting disability in 12 months

Synchron/Stentrode BCI

JAMA Neurology published the SWITCH study of four Australian patients with severe paralysis who received Stentrode implants through the jugular vein. Over 12 months, there were no device-related serious adverse events, no neurological deficits, and stable signal quality throughout.

• Four patients implanted at Royal Melbourne Hospital with no serious adverse events over 12 months
• Stentrode delivered through jugular vein to sagittal sinus without open-brain surgery
• No clots or device migration; signal quality remained stable
• All patients successfully learned to control a computer with the implant